Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
223.19
-3.41 (-1.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
38
39
Next >
2 Moonshot Biotechs with 10x Potential
November 22, 2021
This strategy identified LGVN stock a month ago, and now its price has skyrocketed. Here are two more biotechs that could do the same.
Via
InvestorPlace
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the...
Via
Benzinga
Exposures
Product Safety
Where Biogen Stands With Analysts
November 19, 2021
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the ...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
European Regulator Votes Down Biogen's Alzheimer's Drug
November 17, 2021
Following an oral explanation held at the November meeting of the EMA's human medicines committee, Biogen Inc (NASDAQ: BIIB) received "a negative trend vote...
Via
Benzinga
Biogen Stock Skids After Alzheimer's Drug Aduhelm Faces A Setback In Europe
November 17, 2021
The committee voted against recommending Aduhelm approval.
Via
Investor's Business Daily
Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
November 17, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc. (NASDAQ:
Via
Benzinga
Could Eli Lilly Leapfrog Biogen in This Market?
November 17, 2021
Biogen is benefiting from a first-mover advantage, but the race is far from over.
Via
The Motley Fool
Europe OKs Biogen's Vumerity For Multiple Sclerosis
November 16, 2021
The European Commission has approved Biogen Inc's (NASDAQ: BIIB) Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS...
Via
Benzinga
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
November 16, 2021
Warren Buffet's Berkshire Hathaway added more than 13 million shares.
Via
Investor's Business Daily
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
November 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis...
Via
Benzinga
Google, Tesla Rival XPeng Lead 5 Stocks Near Buy Zones
November 13, 2021
A FANG giant and Tesla rival are among this diverse group.
Via
Investor's Business Daily
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
November 12, 2021
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products.
Via
Talk Markets
President Biden Nominates Robert Califf As New FDA Commissioner: Report
November 12, 2021
Robert Califf was nominated today to lead the FDA for a second time. The White House reportedly ruled out Janet Woodcock after she faced opposition from some members of...
Via
Benzinga
Exposures
Product Safety
Why Are Biogen Shares Gaining Today?
November 12, 2021
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related:...
Via
Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
November 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...
Via
Benzinga
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
November 11, 2021
Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across...
Via
Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &...
Via
Benzinga
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
November 10, 2021
With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition....
Via
Benzinga
This Company Says Its New Topical Therapy Trials Bringing Hope to People Exposed to Biofilm Bacteria
November 09, 2021
Photo by Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...
Via
Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
November 06, 2021
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see...
Via
Talk Markets
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Exposures
COVID-19
Healthcare Stocks Subject to Government Policy
November 02, 2021
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cassava Stock Could Jump More Than 200 Times
November 01, 2021
Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock.
Via
InvestorPlace
Biogen Beat Earnings and Raised Guidance. Here's Why I Still Wouldn't Buy the Stock
October 29, 2021
Aduhelm remains a big question mark for the company.
Via
The Motley Fool
Will Chart Analysts Notice Bad Omen on Biogen's Chart
October 29, 2021
If history is any guide, there may be trouble ahead for shares of Biogen (NASDAQ:BIIB). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.